イマイ カズオ   IMAI Kazuo
  今井 一男
   所属   埼玉医科大学  医学部 臨床検査医学(中央検査部)
   職種   専任講師
論文種別 学術雑誌(原著)
言語種別 英語
査読の有無 査読なし
表題 Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
掲載誌名 正式名:Journal of medical virology
巻・号・頁 94(1),335-341頁
著者・共著者 Yutaro Kitagawa,Kazuo Imai,Masaru Matsuoka,Ai Fukada,Katsumi Kubota,Momoko Sato,Tomohito Takada,Sakiko Noguchi,Norihito Tarumoto,Shigefumi Maesaki,Shinichi Takeuchi,Takuya Maeda
発行年月 2022/01
概要 Fully automated immunoassays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies that are strongly correlated with neutralization antibodies (nAbs) are clinically important because they enable the assessment of humoral immunity after infection and vaccination. Access SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) II antibody tests are semi-quantitative, fully automated immunoassays that detect anti-receptor-binding domain (RBD) antibodies and might reflect nAb levels in coronavirus disease 2019 (COVID-19). However, no studies have investigated the clinical utility of these tests in association with nAbs to date. To evaluate the clinical utility of Access SARS-CoV-2 IgM and IgG II antibody tests and their correlation with the SARS-CoV-2 surrogate virus neutralization test (sVNT) that measures nAbs in patients with COVID-19, we analyzed 54 convalescent serum samples from COVID-19 patients and 89 serum samples from non-COVID-19 patients. The presence of anti-RBD antibodies was detected using Access SARS-CoV-2 IgM and IgG II antibody tests, while nAbs were measured by sVNT. The sensitivity and specificity of sVNT were 94.4% and 98.9%, res
DOI 10.1002/jmv.27338
PMID 34524695